The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in ...
By performing reconstitutions semi-annually, Bloomberg’s indices strike an effective balance of keeping indices well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback